Self-Directed Review in GCRA - Bundle 3 | Hereditary Breast and Ovarian Cancer Syndromes

September 1, 2024

Identifying hereditary cancer predisposition through genetic cancer risk assessment (GCRA) allows for intensified measures to prevent cancers or detect them at an earlier, more treatable stage. Once delivered primarily through academic health centers, the demand for GCRA services in the community setting is steadily increasing.  There is a surge in demand for GCRA services across the nation, but too few clinicians with adequate training to provide GCRA services.  

The increasing demand for GCRA services has been fueled by the rapid evolution of genetic information and direct-to-consumer marketing by commercial genetic testing vendors. 

Target Audience

Physicians, Physician Assistants, Genetic Counselors, Master's or PhD in Genetics or Advanced Practice Nurses, and  Geneticists.

Learning Objectives

  • Recognize features of high-penetrance hereditary breast/breast and ovarian cancer syndromes.
  • Describe the established and emerging genetic etiologies of breast and ovarian cancer.
  • Review the impact of founder mutations associated with BRCA 1 & 2 hereditary breast and ovarian cancer.
  • Examine the benefits and limitations of genetic analysis and risk management for hereditary breast/breast ovarian cancer.
  • Describe the differences between high, moderate, and low penetrance cancer susceptibility genes.
  • Recognize that cancer susceptibility genes on clinical panels are not always actionable.
  • Identify the benefits and limitations in moderate and low penetrance cancer susceptibility genes in clinical multi gene testing panels.
  • Apply mutation probability and empiric risk assessment models for breast cancer.
  • Formulate an evaluation & management plan.
  • Describe the methods and efficacy of breast and ovarian cancer screening tools.
  • Describe the methods and efficacy of breast and ovarian cancer surgical risk reduction.
  • Review the NCCN guidelines for high-risk cancer screening and management.
  • Recognize the timing of GCRA and impact on surgical decisions.
  • Discuss targeted treatment options for patients with germline HRD mutations.
  • Identify tools and strategies for personalized on-surgical breast cancer risk reduction.
  • Describe the benefits and risks of chemopreventive risk reduction strategies and appropriateness for age, life phase and risk level.
  • Review evidence related to lifestyle interventions to reduce breast cancer risk (diet, exercise, etc.).
  • Recognize approaches for testing new interventions for breast cancer risk reduction.
  • Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Activity summary
Available credit: 
  • 7.25 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this Self-Directed Review in GCRA - Bundle 3 | Hereditary Breast and Ovarian Cancer Syndromes for a maximum of 7.25 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 7.25 Attendance
Activity opens: 
09/01/2023
Activity expires: 
09/01/2024
Event starts: 
09/01/2024 - 11:59pm PDT
Event ends: 
09/01/2024 - 11:59pm PDT
Add to calendar: 
Internet

This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.

As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months. Faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships with any ineligible company, which is defined as any entity whose primary business is to produce, market , sell, re-sell or distribute healthcare products used by or on patients. To comply with more intense scrutiny by accreditation agencies, content whose faculty has disclosed any relevant financial relationships with an ineligible company, have been peer reviewed prior to presenting and any potential conflicts relative to the previous disclosure have been resolved.

Presenters/Planners: Listing of Faculty and respective Disclosures

The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.

CME Committee/Reviewer Nothing to Disclose:  Daneng Li, MD

City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.

The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.

This activity has received no commercial support.

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 7.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

•  AMA PRA Category 1 Credit™ 7.25

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 7.25 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.

Available Credit

  • 7.25 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this Self-Directed Review in GCRA - Bundle 3 | Hereditary Breast and Ovarian Cancer Syndromes for a maximum of 7.25 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 7.25 Attendance
Please login or register to take this activity.